Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:

NCT ID: NCT03173807 Not yet recruiting - Prostate Cancer Clinical Trials

Prostate Nutrition and Exercise STudy (ProNEST)

ProNEST
Start date: August 31, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to test the feasibility of nutrition and exercise counseling program for reducing the incidence of metabolic syndrome in prostate cancer patients on Androgen Deprivation Therapy.

NCT ID: NCT03169933 Completed - Prostate Cancer Clinical Trials

Combined, Intensified and Modulated Adjuvant Therapy in Prostate Carcinoma

Start date: January 2, 2004
Phase: Phase 2
Study type: Interventional

Patients with high risk prostate cancer may benefit from radiotherapy after radical prostatectomy. The investigators postulated that adjuvant androgen deprivation therapy (ADT), radiation dose escalation, and selective pelvic irradiation may improve outcome. A phase II trial was designed to prove that combined-intensified-modulated-adjuvant (CIMA) treatment may improve 5-year biochemical relapse free survival (bRFS) from 75% to 90% in high risk patients. The delivered dose to tumor bed and pelvic nodes was 64.8-70.2 Gy and 45 Gy (57% of patients), respectively, and 69% received ADT.

NCT ID: NCT03164837 Recruiting - Prostate Cancer Clinical Trials

68Ga-NOTA-RM26 PET/CT in Prostate Cancer Patients

Start date: November 2016
Phase: Phase 1
Study type: Interventional

This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-RM26 in prostate cancer patients. A single dose of 111-148 Mega-Becquerel (MBq) 68Ga-NOTA-RM26 will be injected intravenously. Visual and semiquantitative method will be used to assess the PET/CT images.

NCT ID: NCT03162523 Completed - Prostate Cancer Clinical Trials

Experiences With HDR-brachytherapy in Norway

Start date: January 2004
Phase: N/A
Study type: Observational [Patient Registry]

There are 3 articles that will be written about the experience with HDR-brachytherapy (HDR-BT) in patients with high-risk prostate cancer in Norway as part of a doctorial thesis-project. The project will focus on survival, side-effects and dosimetry variables as the main points of interest.

NCT ID: NCT03162003 Active, not recruiting - Prostate Cancer Clinical Trials

Irish Programme for Stratified Prostate Cancer Therapy

iPROSPECT
Start date: February 2015
Phase: N/A
Study type: Observational

The purpose of the trial is to investigate new clinical tests that could predict what treatments work best for certain patients with advanced prostate cancer by identifying markers and indicators present in blood and tissue which correlate with treatment response.

NCT ID: NCT03160365 Not yet recruiting - Prostate Cancer Clinical Trials

Innovative Planning and Guidance System for Prostate Focal Brachytherapy

FOCUS
Start date: September 4, 2017
Phase: N/A
Study type: Interventional

A key feature of low-dose brachytherapy is that irradiation affects only a local area around the inserted radiation sources. The exposure of healthy tissues around these sources is then reduced. However, the number of adverse events remains high (about 79% of patients with sexual problems and 30% of patients with urinary incontinence) and brachytherapy is no better than other treatment options for Preservation of the urethral apparatus (about 40% of patients). The current technique for the implantation of radioactive sources, which has not been revised since the early 1980s, consists in imaging the prostate at the beginning of the intraoperative procedure with transrectal ultrasound in order to evaluate the size and shape of the prostate . This information is then used to identify the best distribution of the dose of radiation to be administered to each patient. This treatment planning step is based on a procedure where the operator manually places 50 to 100 grains of iodine in the prostate. These grains are inserted transperinally under transrectal 2D ultrasound control, using needles through a transperineal grid with several needle guides evenly spaced 5 mm apart. This is an arduous task because this manual grain placement procedure must take into account the dose to be administered to the prostate without exceeding the dose limit for the surrounding organs at risk (rectum, urethra). In addition, the overestimation of the dose formality called TG-43 and the inaccurate grain placement can contribute to the creation of cold spots where no dose is administered. It may be responsible for recurrences of prostate cancer after brachytherapy treatment. Although brachytherapy dosimetry has been extensively researched, the TG-43 dose formalism has been the benchmark for the last 20 years. Moreover, from an economic point of view, the high side-effects rates of the treatment of prostate cancer result in particularly expensive post-treatment costs. The search for improved solutions for the treatment of prostate cancer remains a major societal challenge. In recent years, a very attractive therapeutic alternative between active surveillance and overall treatment is gaining popularity among experts: focal therapy. It is a localized treatment, limited to cancerous areas, in order to preserve healthy functional tissues inside and outside the organ and thus the quality of life of the patient. Focal therapy is also often the preferred solution for recovery therapy (second intervention). Finally, focal therapy has great potential to reduce the cost and duration of the intervention, as well as the cost of follow-up. In recent years, several energies have been proposed as being adapted to focal therapy, such as high intensity focal ultrasound, laser ablation and cryotherapy. Brachytherapy, which already gives above average results in the treatment of whole glands, has been identified as a very good candidate for this new therapeutic paradigm. In brachytherapy, radioactive grains are implanted in the prostate using transperineal catheters. The rapid reduction of the dose according to the distance of the radioactive seeds gives the physician a great flexibility to control the radiation accurately. It allows intermediate approaches between global and focal treatments, providing great scalability, and it is a good candidate for recovery therapy. Recent studies have shown that focal brachytherapy allows more than half of the needles and seeds to act more strongly on the target while irradiating Significantly less The urethra and rectum. Clinical studies on this subject are still limited and further research is needed to confirm the performance of this approach.

NCT ID: NCT03159676 Recruiting - Prostate Cancer Clinical Trials

Proton-Based Stereotactic Ablative Body Radiotherapy for Patients With Localized Prostate Cancer

Start date: May 12, 2017
Phase: N/A
Study type: Observational

Patients will receive proton beam-based SABR as standard of care. Standard of care will include clinical examinations and testing (serum prostate-specific antigen levels, computed tomography, magnetic resonance imaging, urodynamics, bone scan, proton beam therapy dosimetry), and in follow-up monitoring of quality of life.

NCT ID: NCT03158922 Recruiting - Prostate Cancer Clinical Trials

The BARCODE 1 Study

BARCODE1Pilot
Start date: April 29, 2016
Phase: N/A
Study type: Observational

BARCODE 1 is a screening study designed to investigate the role of genetic profiling for targeting population prostate cancer screening. This study forms a pilot of 300 men, with the view to continue to a future study of 5000 men.

NCT ID: NCT03157947 Not yet recruiting - Prostate Cancer Clinical Trials

Culturally Tailored Decision Aid for Hispanic Patients Diagnosed With Prostate Cancer

Start date: September 2017
Phase: N/A
Study type: Interventional

A pilot study testing the effect of an in-visit English and Spanish language decision aid for Hispanic-Latino men using best practices of cultural tailoring to be used in urology practice. Subjects will be followed for approximately 1 year during standard care in-clinic office visits. Study results and subject surveys will be analyzed to determine clinical utility of the tool.

NCT ID: NCT03156244 Recruiting - Prostate Cancer Clinical Trials

Using PROMIS as Part of Routine Clinical Care for Racially Diverse Prostate and Bladder Cancer Patients

Start date: May 8, 2017
Phase: N/A
Study type: Observational

In this pilot study, a total of 80 patients with prostate or bladder cancer (40 black, 40 white) will complete 3 patient-reported outcome (PRO) surveys: baseline (pre-treatment), during treatment, and after treatment. The overall goal of this study is to assess whether collecting patient-reported data is feasible as part of clinical care of cancer patients, and whether these data are useful for clinicians and patients. Among these 80 patients, those who agree will also undergo a semi-structured interview to assess value of HRQOL assessment at the end of the study. Of specific interest is an evaluation of whether feasibility and perceived value differ between black and white participants.